

In brief

Emerging variants

13 May 2022

Summary

- The World Health Organization is monitoring BA.1, BA.2, BA.3, BA.4, BA.5 and descendent lineages and BA.1/BA.2 circulating recombinant forms such as XE under Omicron; however, the World Health Organization advises that public health authorities should monitor descendant lineages as distinct lineages.¹
- Variants under monitoring listed by the World Health Organization include B.1.640 and XD recombinant (Delta AY.4 and Omicron BA.1).¹
- Three Omicron sublineages BA.4, BA.5 and BA.2.12.1 have acquired additional mutations that may impact their characteristics (BA.4 and BA.5 have the del69/70, L452R and F486V mutations; BA.2.12.1 has the L452Q and S704L mutations).²

BA.2.12.1

- In the week ending 30 April 2022, BA.2.12.1 made up [36.5%](#) of all newly sequenced positive COVID-19 tests in the United States.³
- Preliminary data suggests that [BA.2.12.1](#) exhibits increased ACE2-binding affinities compared to BA.1.⁴
- Early data suggests use of [pOGTF as a proxy for BA.2.12.1](#) provides faster tracking than whole genome sequencing.⁵
- Early reports of a growth advantage for [BA.2.12 over BA.2](#).⁶
- There are evaluations on the sensitivity of BA.2.12.1 to eight therapeutic monoclonal antibodies. Findings from [two studies](#) suggest several antibodies are less effective against BA.2.12.1.^{7, 8}

BA.4 and BA.5

- In a risk assessment published by [the United Kingdom Health Security Agency on 28 April 2022](#) on BA.4 and BA.5 sublineages there was:
 - evidence of an overall growth advantage (red status with low level confidence) compared to BA.2 in the context of South Africa
 - insufficient data to report on transmissibility
 - evidence of some antigenic change (red status with moderate level confidence) compared to BA.2 based on structural modelling and pseudovirus neutralisation data
 - insufficient data to report on infection severity.⁹
- The [European Centre for Disease Prevention and Control](#) reported no current evidence for impact on transmissibility or on severity for BA.4 and BA.5 on 5 May 2022. However, early data suggests increased impact on immunity.
- Mutation profiles:

- BA.4 shares all mutations and deletions with the BA.2 lineage except the following:
 - S: 69/70 deletion, R408 (WT), L452R, F486V, Q493 (WT)
 - ORF 7b: L11F
 - N: P151S
 - synonymous SNP G12160A.
- BA.5 shares all mutations and deletions with the BA.2 lineage except the following:
 - S: 69/70 deletion, R408 (WT), L452R, F486V, Q493 (WT)
 - ORF6: D61 (wild type)
 - M: D3N
 - synonymous SNPs: G12160A, A27038G, and C27889T.¹⁰
- Preliminary data suggests BA.4 and BA.5 sequences have the 69-70 deletion responsible for S gene target failure (SGTF).²
- Early reports suggest the [observed escape of BA.4 and BA.5](#) from BA.1 elicited immunity is more moderate than the escape of BA.1 from previous immunity.^{4, 11} One study showed that the BA.1 infection elicited neutralising capacity against BA.4 and BA.5 was five-fold higher in vaccinated individuals (Comirnaty and Johnson & Johnson) than unvaccinated individuals.¹¹
- [BA.4 and BA.5](#) have rapidly replaced BA.2, reaching more than 50% of sequenced cases in South Africa.¹² Estimated growth advantages for BA.4 and BA.5 are 0.08 and 0.12 per day respectively over BA.2 in South Africa.¹²
- According to the [National Institute for Communicable Disease from South Africa](#), as of 4 May 2022, there was no indication that the BA.4 and BA.5 will increase the risk of developing severe disease in South Africa. However, the situation will continue to be monitored.¹³
- A [preliminary comparative analysis](#) and modelling study projected that the BA.4 and BA.5 are about 36% more infectious than BA.2 and will likely to become the new dominant variant.¹⁴
- Evaluations on the sensitivity of BA.2.12.1 and BA.4/5 to eight therapeutic [monoclonal antibodies](#) (bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab, sotrovimab and tixagevimab) showed that bebtelovimab had two-fold more neutralising activity against BA.2 and other Omicron subvariants than against the parental virus (B.1.1). Sotrovimab had a 20-fold reduced neutralising activity against BA.2 than against the parental virus, however, it had more neutralising activity against BA.2.11 and BA.4/5 than against BA.2. Cilgavimab was active against BA.2, however, in comparison had 2-5-fold reduction in neutralising activity against BA.2.12.1 and 30-fold reduction against BA.4/5.⁷

Recombinant lineages

- There are reports of three recombinant lineages: [XD, XE and XF](#).¹⁵ The United Kingdom Health Security Agency identified two different combinations of Delta and BA.1 (XD and XF).¹⁵
- XD and XF are combinations of Delta AY.4 and BA.1. XD has the Omicron S gene incorporated into a Delta genome. XE is a combination of BA.1 and BA.2, with most of the genome including the S gene belonging to BA.2.¹⁵
- The [XD recombinant](#) is a variant under monitoring by the World Health Organisations and XE is monitored as Omicron.¹⁶

- It is estimated that XE has a growth rate 12.6% above that of BA.2.¹⁷
- There are reports that [XF is no longer detected](#) in the European Union and European Economic Area.¹⁰
- Early data suggests [Delta-Omicron recombinant infections](#) are rare and there is no evidence of increased transmissibility compared to other Omicron lineages.¹⁸
- Early reports suggest there is [no current evidence that XD](#) is associated with higher transmissibility or more severe outcomes.¹⁹

References

1. World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Geneva: WHO; 2022 [cited 2022 May 09]. Available from: <https://www.who.int/activities/tracking-SARS-CoV-2-variants>
2. World Health Organization. Weekly epidemiological update on COVID-19 - 4 May 2022 [Internet]. Geneva: WHO; 2022 May 04 [cited 2022 May 09]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-may-2022>
3. Centres for Disease Control and Prevention (CDC). COVID data tracker: variant proportions [Internet]. United States: CDC; 2022 April 30 [cited 2022 May 09]. Available from: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>
4. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. bioRxiv. 2022:2022.04.30.489997. DOI: 10.1101/2022.04.30.489997
5. Rodino KG, Peaper DR, Kelly BJ, et al. Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1. medRxiv. 2022:2022.04.25.22274187. DOI: 10.1101/2022.04.25.22274187
6. World Health Organization. Weekly epidemiological update on COVID-19 - 27 April 2022 [Internet]. Geneva: WHO; 2022 Apr 27 [cited 2022 May 09]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---27-april-2022>
7. Yamasoba D, Kosugi Y, Kimura I, et al. Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies. bioRxiv. 2022:2022.05.03.490409. DOI: 10.1101/2022.05.03.490409
8. Arora P, Zhang L, Krüger N, et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe. DOI: 10.1016/j.chom.2022.04.017
9. UK Health Security Agency (UKHSA). Risk assessment for SARS-CoV-2 variants V-22APR-03 and V-22APR-04 [Internet]. United Kingdom: UKHSA; 2022 Apr 28 [cited 2022 May 09]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/107361/28-april-2022-risk-assessment-for-V-22APR-03-and-V-22APR-04-2.pdf
10. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern as of 5 May 2022 [Internet]. Sweden: ECDC; 2022 May 05 [cited 2022 May 09]. Available from: <https://www.ecdc.europa.eu/en/covid-19/variants-concern>
11. Khan K, Karim F, Ganga Y, et al. Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. medRxiv. 2022:2022.04.29.22274477. DOI: 10.1101/2022.04.29.22274477
12. Tegally H, Moir M, Everatt J, et al. Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages. medRxiv. 2022:2022.05.01.22274406. DOI: 10.1101/2022.05.01.22274406
13. National Institute for Communicable Disease. Omicron lineages BA.4 and BA.5 FAQ [Internet]. South Africa: NICD; 2022 May 04 [cited 2022 May 09]. Available from: <https://www.nicd.ac.za/omicron-lineages-ba-4-and-ba-5-faq/>

14. Chen J, Qiu Y, Wang R, et al. Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants [Internet]. arxiv; 2022 May 01 [cited 2022 May 09]. Available from: <https://arxiv.org/abs/2205.00532>
15. UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. United Kingdom: UKHSA; 2022 Mar 25 [cited 2022 May 09]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf
16. World Health Organization. Weekly epidemiological update on COVID-19 - 5 April 2022 [Internet]. Geneva: WHO; 2022 Apr 05 [cited 2022 May 09]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---5-april-2022>
17. UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. United Kingdom: UKHSA; 2022 Apr 08 [cited 2022 May 09]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1067672/Technical-Briefing-40-8April2022.pdf
18. Bolze A, Basler T, White S, et al. Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination. medRxiv. 2022:2022.03.09.22272113. DOI: 10.1101/2022.03.09.22272113
19. Mohapatra RK, Kandi V, Tuli HS, et al. The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic. J Med Virol. 2022 2022/04/13;n/a(n/a). DOI: <https://doi.org/10.1002/jmv.27780>

SHPN: (ACI) 220365 | TRIM: ACI/D22/51-19 | Edition 1